Freenome (NASDAQ:FRNM) Sets New 12-Month High – What’s Next?

Freenome (NASDAQ:FRNM)’s share price reached a new 52-week high during trading on Tuesday . The stock traded as high as $15.25 and last traded at $15.1950, with a volume of 79090 shares. The stock had previously closed at $14.79.

Analyst Upgrades and Downgrades

FRNM has been the topic of a number of research analyst reports. Weiss Ratings began coverage on shares of Freenome in a report on Monday, August 24th. They issued a “sell (d+)” rating on the stock. Guggenheim initiated coverage on shares of Freenome in a research report on Thursday, August 20th. They set a “buy” rating and a $21.00 target price for the company. Jefferies Financial Group started coverage on Freenome in a research note on Monday, August 17th. They set a “buy” rating and a $17.00 price target for the company. TD Cowen started coverage on Freenome in a report on Tuesday, August 18th. They issued a “buy” rating and a $17.00 price objective for the company. Finally, BTIG Research began coverage on Freenome in a research note on Monday, August 17th. They issued a “buy” rating and a $17.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Freenome Trading Up 1.1%

The company has a market capitalization of $1.61 billion, a PE ratio of -249.81 and a beta of 0.35.

About Freenome

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. The company combines artificial intelligence with multiomics analysis, examining biological signals in blood—including genetic, immune and other molecular indicators—to identify cancer-related patterns.

Freenome’s research and development efforts have focused on noninvasive screening for colorectal cancer, with additional programs targeting other cancers. Its platform is intended to support earlier detection and may also have applications in cancer monitoring and treatment-related decision-making.

Founded in 2014 and based in California, Freenome has pursued collaborations with healthcare and biopharmaceutical organizations to advance its testing technology.